CN101821234A - 苯氧基吡咯烷衍生物及其应用和组合物 - Google Patents
苯氧基吡咯烷衍生物及其应用和组合物 Download PDFInfo
- Publication number
- CN101821234A CN101821234A CN200880111278A CN200880111278A CN101821234A CN 101821234 A CN101821234 A CN 101821234A CN 200880111278 A CN200880111278 A CN 200880111278A CN 200880111278 A CN200880111278 A CN 200880111278A CN 101821234 A CN101821234 A CN 101821234A
- Authority
- CN
- China
- Prior art keywords
- compound
- phenoxy group
- treatment
- pharmacology
- tetramethyleneimine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
时间(min) | 溶剂A(%) | 溶剂B(%) | 流速(mL/min) |
0 | 99 | 1 | 2 |
2 | 96 | 4 | 2 |
6 | 60 | 40 | 2 |
时间(min) | 溶剂A(%) | 溶剂B(%) | 流速(mL/min) |
7 | 5 | 95 | 2 |
10 | 5 | 95 | 2 |
10.1 | 99 | 1 | 2 |
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410216236.9A CN104292144B (zh) | 2007-08-08 | 2008-07-28 | 苯氧基吡咯烷衍生物及其应用和组合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95459307P | 2007-08-08 | 2007-08-08 | |
US60/954,593 | 2007-08-08 | ||
PCT/IB2008/002028 WO2009019566A1 (en) | 2007-08-08 | 2008-07-28 | Phenoxy-pyrrolidine derivative and its use and compositions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410216236.9A Division CN104292144B (zh) | 2007-08-08 | 2008-07-28 | 苯氧基吡咯烷衍生物及其应用和组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101821234A true CN101821234A (zh) | 2010-09-01 |
CN101821234B CN101821234B (zh) | 2014-06-25 |
Family
ID=39870001
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880111278.9A Active CN101821234B (zh) | 2007-08-08 | 2008-07-28 | 苯氧基吡咯烷衍生物及其应用和组合物 |
CN201410216236.9A Active CN104292144B (zh) | 2007-08-08 | 2008-07-28 | 苯氧基吡咯烷衍生物及其应用和组合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410216236.9A Active CN104292144B (zh) | 2007-08-08 | 2008-07-28 | 苯氧基吡咯烷衍生物及其应用和组合物 |
Country Status (14)
Country | Link |
---|---|
US (3) | US8242286B2 (zh) |
EP (1) | EP2173711B1 (zh) |
JP (2) | JP5239001B2 (zh) |
KR (1) | KR101189189B1 (zh) |
CN (2) | CN101821234B (zh) |
AT (1) | ATE488499T1 (zh) |
AU (1) | AU2008285255B2 (zh) |
BR (1) | BRPI0815048B8 (zh) |
CA (1) | CA2695664C (zh) |
DE (1) | DE602008003586D1 (zh) |
ES (1) | ES2352098T3 (zh) |
MX (1) | MX2010001485A (zh) |
RU (1) | RU2010107892A (zh) |
WO (1) | WO2009019566A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8980936B2 (en) | 2007-08-08 | 2015-03-17 | Thesan Pharmaceuticals, Inc. | Phenoxy-pyrrolidine derivative and its use and compositions |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2948939B1 (fr) | 2009-08-05 | 2013-03-22 | Pf Medicament | Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine |
FR2958935B1 (fr) * | 2010-04-19 | 2012-06-22 | Pf Medicament | Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine |
BR112012026875B1 (pt) | 2010-06-11 | 2018-12-04 | Avon Products, Inc. | método cosmético para melhorar a aprência da pele afetada pela celulilte e para reduzir recorrência de celulite em uma área previamente afetada e kit |
EP2766000A2 (en) | 2011-10-15 | 2014-08-20 | F.Hoffmann-La Roche Ag | Scd1 antagonists for treating cancer |
WO2013134546A1 (en) | 2012-03-07 | 2013-09-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
US10405795B1 (en) | 2013-03-15 | 2019-09-10 | The Procter & Gamble Company | Methods of classifying periorbital dyschromia and systems therefor |
JP2016527307A (ja) * | 2013-08-08 | 2016-09-08 | ガルデルム セラピューティクス リミテッド | 胆汁酸−脂肪酸抱合体を含む抗座瘡組成物 |
US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
KR20170000657U (ko) | 2015-08-11 | 2017-02-21 | 김유호 | 골프연습기 |
WO2017214201A1 (en) | 2016-06-06 | 2017-12-14 | Thesan Pharmaceuticals, Inc. | Formulations for substituted 3-pyrrolidines, compositions containing, and uses of, same |
WO2018081167A1 (en) | 2016-10-24 | 2018-05-03 | Yumanity Therapeutics | Compounds and uses thereof |
EA201991650A1 (ru) | 2017-01-06 | 2020-01-20 | Юманити Терапьютикс, Инк. | Способы лечения неврологических расстройств |
EP3700934A4 (en) | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THESE COMPOUNDS |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH432495A (de) * | 1964-02-04 | 1967-03-31 | Geigy Ag J R | Verfahren zur Herstellung neuer Aryloxyessigsäureamide |
CA2067514A1 (en) | 1991-05-10 | 1992-11-11 | Sergiu Mircea Gorun | Manganese oligomer containing main group elements |
US6338144B2 (en) | 1999-02-19 | 2002-01-08 | Sun Microsystems, Inc. | Computer system providing low skew clock signals to a synchronous memory unit |
US20050119251A1 (en) | 2001-12-21 | 2005-06-02 | Jian-Min Fu | Nicotinamide derivatives and their use as therapeutic agents |
ATE556056T1 (de) | 2003-07-29 | 2012-05-15 | Xenon Pharmaceuticals Inc | Pyridylderivate und deren verwendung als therapeutische mittel |
ES2375134T3 (es) | 2003-07-30 | 2012-02-27 | Xenon Pharmaceuticals Inc. | Derivados de piperazina y su uso como agentes terapéuticos. |
CN101693697A (zh) | 2003-07-30 | 2010-04-14 | 泽农医药公司 | 哌嗪衍生物和它们作为治疗剂的用途 |
EP1651606B1 (en) | 2003-07-30 | 2012-10-24 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
HUP0401526A2 (en) * | 2004-07-29 | 2006-04-28 | Richter Gedeon Vegyeszet | Aryloxy acetic acid amide derivatives, pharmaceutical compositions comprising thereof, methods for their preparation and their use |
CA2615045A1 (en) * | 2005-07-20 | 2007-01-25 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
CA2654098A1 (en) * | 2006-06-13 | 2007-12-21 | Merck Frosst Canada Ltd. | Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
CN101821234B (zh) | 2007-08-08 | 2014-06-25 | 格里斯威医药有限责任公司 | 苯氧基吡咯烷衍生物及其应用和组合物 |
-
2008
- 2008-07-28 CN CN200880111278.9A patent/CN101821234B/zh active Active
- 2008-07-28 ES ES08788986T patent/ES2352098T3/es active Active
- 2008-07-28 RU RU2010107892/04A patent/RU2010107892A/ru not_active Application Discontinuation
- 2008-07-28 MX MX2010001485A patent/MX2010001485A/es not_active Application Discontinuation
- 2008-07-28 US US12/670,010 patent/US8242286B2/en active Active
- 2008-07-28 CN CN201410216236.9A patent/CN104292144B/zh active Active
- 2008-07-28 WO PCT/IB2008/002028 patent/WO2009019566A1/en active Application Filing
- 2008-07-28 CA CA2695664A patent/CA2695664C/en active Active
- 2008-07-28 EP EP08788986A patent/EP2173711B1/en active Active
- 2008-07-28 BR BRPI0815048A patent/BRPI0815048B8/pt active IP Right Grant
- 2008-07-28 AT AT08788986T patent/ATE488499T1/de not_active IP Right Cessation
- 2008-07-28 DE DE602008003586T patent/DE602008003586D1/de active Active
- 2008-07-28 KR KR1020107001820A patent/KR101189189B1/ko active IP Right Grant
- 2008-07-28 AU AU2008285255A patent/AU2008285255B2/en active Active
- 2008-07-28 JP JP2010519537A patent/JP5239001B2/ja active Active
-
2012
- 2012-07-13 US US13/549,299 patent/US8524761B2/en active Active
-
2013
- 2013-03-05 JP JP2013043265A patent/JP5805119B2/ja active Active
- 2013-07-18 US US13/945,622 patent/US8980936B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8980936B2 (en) | 2007-08-08 | 2015-03-17 | Thesan Pharmaceuticals, Inc. | Phenoxy-pyrrolidine derivative and its use and compositions |
Also Published As
Publication number | Publication date |
---|---|
KR20100040878A (ko) | 2010-04-21 |
US20140045911A1 (en) | 2014-02-13 |
MX2010001485A (es) | 2010-06-01 |
US8242286B2 (en) | 2012-08-14 |
JP2013100377A (ja) | 2013-05-23 |
ES2352098T3 (es) | 2011-02-15 |
CA2695664A1 (en) | 2009-02-12 |
EP2173711B1 (en) | 2010-11-17 |
RU2010107892A (ru) | 2011-09-27 |
CN101821234B (zh) | 2014-06-25 |
JP2010535756A (ja) | 2010-11-25 |
AU2008285255B2 (en) | 2012-09-27 |
WO2009019566A1 (en) | 2009-02-12 |
CN104292144A (zh) | 2015-01-21 |
US20100247471A1 (en) | 2010-09-30 |
ATE488499T1 (de) | 2010-12-15 |
BRPI0815048A2 (pt) | 2016-04-05 |
EP2173711A1 (en) | 2010-04-14 |
BRPI0815048B8 (pt) | 2021-05-25 |
US20120277280A1 (en) | 2012-11-01 |
KR101189189B1 (ko) | 2012-10-10 |
CN104292144B (zh) | 2017-05-17 |
US8524761B2 (en) | 2013-09-03 |
DE602008003586D1 (de) | 2010-12-30 |
JP5805119B2 (ja) | 2015-11-04 |
CA2695664C (en) | 2014-12-09 |
BRPI0815048B1 (pt) | 2020-09-29 |
AU2008285255A1 (en) | 2009-02-12 |
US8980936B2 (en) | 2015-03-17 |
JP5239001B2 (ja) | 2013-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101821234B (zh) | 苯氧基吡咯烷衍生物及其应用和组合物 | |
CN103479654B (zh) | 作为抗炎药的含硼的小分子 | |
CN111511729A (zh) | Tlr7/8拮抗剂及其用途 | |
EP0346431B1 (en) | Onset-hastened/enhanced analgesia using s(+) ketoprofen | |
JP3887020B2 (ja) | アズレニルニトロンスピントラッピング剤、ならびにその製造方法および使用方法 | |
JP2007535558A (ja) | キナーゼおよび/またはhmg−coaレダクターゼを阻害するための組成物および処置 | |
CN105530940A (zh) | 乙酰辅酶a羧化酶抑制剂用于治疗寻常痤疮的用途 | |
Krištofiková et al. | In vitro effect of Ginkgo biloba extract (EGb 761) on the activity of presynaptic cholinergic nerve terminals in rat hippocampus | |
TW201505660A (zh) | 類神經醯胺功能賦予劑 | |
US20100317736A1 (en) | Composition of the skin external application or the food for accelerating proline recycling by containing theanine | |
US20200331919A1 (en) | Synergistic compositions comprising (R)-dimiracetam (1) and (S)-dimiracetam (2) in a non-racemic ratio | |
CA2133427C (en) | Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders | |
CA2182882A1 (en) | Cholinesterase activator | |
JP2004331580A (ja) | 中性脂肪蓄積抑制剤 | |
AU2012216754B2 (en) | Phenoxy-pyrrolidine derivative and its use and compositions | |
EP3890833B1 (en) | Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio | |
CN115887435A (zh) | 长链类化合物及其用途 | |
CN104254522A (zh) | 作为trpv3调节剂的甲醇衍生物 | |
US20150259336A1 (en) | Benzothiazole-based Pyridinium Compounds for the Treatment of Neurodegenerative Diseases or Nerve Agent Exposure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GRACEWAY PHARMACEUTICALS LLC Free format text: FORMER OWNER: MEDICIS PHARMACEUTICAL CORP. Effective date: 20150512 Owner name: MEDICIS PHARMACEUTICAL CORP. Free format text: FORMER OWNER: GRACEWAY PHARMACEUTICALS LLC Effective date: 20150512 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150512 Address after: Carlsbad, California, USA Patentee after: Thesan Pharmaceuticals, Inc. Address before: Scottsdale, Arizona Patentee before: Mei ticci, pharmaceutical Co. Effective date of registration: 20150512 Address after: Scottsdale, Arizona Patentee after: Mei ticci, pharmaceutical Co. Address before: Tennessee Patentee before: Griswell Pharmaceutical Co.,Ltd. |